まとめグローバル加齢性黄斑変性症（AMD）治療薬市場は、2015年から2019年までのCAGR xx％でxxx百万米ドルと評価されました。 その後、2020年にはXXX百万米ドルに達し、2020年から2025年までのCAGRはxx％になります。
世界の加齢性黄斑変性症（AMD）治療薬市場では、このレポートは特に北アメリカ、南アメリカ、ヨーロッパとアジア太平洋、および中東とアフリカに焦点を当てています。 このレポートは、アプリケーション、タイプ、地域、および製造業者に基づいて市場を分類します。
メーカー別の市場細分化では、レポートは次の企業をカバーしています-
Amgen Inc.
Novartis AG
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals Inc.
地理的地域による市場細分化では、レポートは次の地域を分析しました-
北米（米国、カナダ、メキシコ）
ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
アジア太平洋（中国、日本、韓国、インド、東南アジア）
南アメリカ（ブラジル、アルゼンチン、コロンビアなど）
中東およびアフリカ（サウジアラビア、アラブ首長国連邦、エジプト、ナイジェリア、南アフリカ）
タイプによる市場細分化：
ウェットAMD
ドライAMD
アプリケーションによる市場細分化：
病院
診療所
研究所
他の
この調査は、次の重要な質問に対する回答を提供します。
• 2020年から2025年の予測期間における加齢性黄斑変性症（AMD）治療薬市場の推定成長率と市場シェアおよび規模はどのくらいですか？
• 予測期間2020年から2025年の加齢性黄斑変性症（AMD）治療薬市場の原動力は何ですか？
• 著名なマーケットプレーヤーは誰ですか？彼らは他の競合他社に対してどのように競争力を獲得しましたか？
• 世界中の加齢性黄斑変性症（AMD）治療薬の業界の進歩に影響を与える市場動向は何ですか？
• 業界の進歩を制限する主な課題と脅威は何ですか？
• 市場は著名な市場プレーヤーにとってどのような機会を持っていますか？
このレポートに関する特別な要件がある場合は、お知らせください。カスタムレポートを提供できます。
注–より正確な市場予測を提供するために、COVID-19の影響を考慮して、すべてのレポートが配信前に更新されます。
Table of Contents
1 Age-Related Macular Degeneration (AMD) Therapeutics Market Overview
1.1 Product Overview and Scope of Age-Related Macular Degeneration (AMD) Therapeutics
1.2 Classification of Age-Related Macular Degeneration (AMD) Therapeutics by Types
1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Comparison by Types (2020-2025)
1.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Types in 2018
1.2.3 Wet AMD
1.2.4 Dry AMD
1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Other
1.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Regions
1.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2015-2025)
1.5 Global Market Size of Age-Related Macular Degeneration (AMD) Therapeutics (2015-2025)
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Business Overview
2.1.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
2.2 Novartis AG
2.2.1 Business Overview
2.2.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
2.3 Bausch Health Companies, Inc.
2.3.1 Business Overview
2.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
2.4 F. Hoffmann-La Roche Ltd.
2.4.1 Business Overview
2.4.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
2.5 Regeneron Pharmaceuticals Inc.
2.5.1 Business Overview
2.5.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2019)
3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Competition, by Players
3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share
3.2.2 Top 10 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Market Share by Regions
4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
4.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
4.5 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
5 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
5.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2015-2019)
5.2 USA Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
5.3 Canada Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
5.4 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
6 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
6.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2015-2019)
6.2 Germany Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
6.3 UK Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
6.4 France Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
6.5 Russia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
6.6 Italy Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2015-2019)
7.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
7.3 Japan Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
7.4 Korea Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
7.5 India Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
8 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
8.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2015-2019)
8.2 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
8.3 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
8.4 Colombia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Age-Related Macular Degeneration (AMD) Therapeutics by Countries
9.1 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2015-2019)
9.2 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
9.3 UAE Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
9.4 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
9.5 Nigeria Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
9.6 South Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2015-2019)
10 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Type
10.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Market Share by Type (2015-2019)
10.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Type (2020-2025)
10.3 Wet AMD Revenue Growth Rate (2015-2025)
10.4 Dry AMD Revenue Growth Rate (2015-2025)
11 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Application
11.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2015-2019)
11.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Application (2020-2025)
11.3 Hospital Revenue Growth (2015-2019)
11.4 Clinic Revenue Growth (2015-2019)
11.5 Research Institute Revenue Growth (2015-2019)
11.6 Other Revenue Growth (2015-2019)
12 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast (2020-2025)
12.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast (2020-2025)
12.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Regions (2020-2025)
12.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2020-2025)
12.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2020-2025)
12.6 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
